1 hat organizing pneumonia was associated with Sweet's syndrome.

2 ivity may have a role in the pathogenesis of Sweet's syndrome.

3 also the clinical features and management of Sweet's syndrome.

4 ions have also been associated with inducing Sweet's syndrome.

5                             Animal models of Sweet's syndrome and new associated medication have been

6 tor, can cause or mimic vasculitides such as Sweet's syndrome and pyoderma gangrenosum.

7 ed cardiac involvement in patients with post-Sweet's syndrome cutis laxa.

8 INDINGS: Some of the new insights concerning Sweet's syndrome include: (1) bortezomib-induced Sweet's

9 ammatory syndrome (relapsing polychondritis, Sweet's syndrome, polyarteritis nodosa, or giant-cell ar

10 t's syndrome include: (1) bortezomib-induced Sweet's syndrome (some of which are the histiocytoid var

11 ic DNA sequences of PTPN6 from patients with Sweet's syndrome (SW) and pyoderma gangrenosum and found

12  neutrophilic infiltrations and diagnosis of Sweet's syndrome was made.

13 , (2) a rare extracutaneous manifestation of Sweet's syndrome with cardiovascular involvement includi